NCT00004871View on ClinicalTrials.gov

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

May 31, 2000

Conditions

LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases

Interventions

DRUG

azacitidine

DRUG

sodium phenylbutyrate

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00004871 - Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter